Skip to main content
Monday, November 16, 2026Nov 16

Switch from selling COVID-19 drugs on market rather than to governments continues to sting at Pfizer

FILE - A man walks by Pfizer headquarters, Friday, Feb. 5, 2021 in New York. Pfizer released a financial outlook for next year that that doesn't match with Wall Street expectations as sales of COVID-19 products slide. Shares tumbled more than 7% before the opening bell Wednesday, Dec. 13, 2023.  (AP Photo/Mark Lennihan, File)
FILE - A man walks by Pfizer headquarters, Friday, Feb. 5, 2021 in New York. Pfizer released a financial outlook for next year that that doesn't match with Wall Street expectations as sales of COVID-19 products slide. Shares tumbled more than 7% before the opening bell Wednesday, Dec. 13, 2023. (AP Photo/Mark Lennihan, File)

Pfizer heads into 2024 with a lower-than-expected sales forecast for its COVID-19 vaccine and treatment after weaker demand had already forced it to trim 2023 projections.

The drugmaker announced on Wednesday initial expectations for the new year that include about $8 billion in combined sales from its Comirnaty vaccine and the treatment Paxlovid. That falls more than $5 billion short of estimates on Wall Street.

The company’s forecast for overall earnings and revenue next year also missed consensus. Pfizer shares continued their largely year-long slide in midday trading.

Pfizer leaders told analysts Wednesday that they expect vaccination and treatment rates to be about the same next year as they were in 2023. But they wanted to be conservative and offer a “good floor” for expectations to avoid creating any more uncertainty, CEO Albert Bourla said.

In mid-October, Pfizer said sales of both the vaccine and treatment were turning out weaker than expected. The company cut revenue projections for this year by $9 billion. Two weeks later, Pfizer said sales of the treatment and vaccine had slid 97% and 70%, respectively, in the third quarter.